Song Li

Dr. Song Li


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
Andreas KalogeropoulosAndreas Kalogeropoulos
Andreas Kalogeropoulos
GFGregg C. Fonarow
Gregg C. Fonarow
VGVasiliki Georgiopoulou
Vasiliki Georgiopoulou
GBGregory Burkman
Gregory Burkman
SSSarawut Siwamogsatham
Sarawut Siwamogsatham
JBJaved Butler
Javed Butler
Heart failure with preserved ejection fraction (HFpEF) has been reported to account for almost half of all heart failure (HF) cases.1-3 In most studies, the morbidity and mortality of HFpEF were similar or comparable to those of HF with reduced ejection fraction (HFrEF).1,2,4-7 Based on the epidemiological link of HFpEF to aging and age-related risk factors and comorbid conditions, the prevalence of HFpEF is projected to rise.1,7 There is also growing evidence that HFpEF is a diverse entity encompassing a wide range of structural and clinical phenotypes.8-10

20 July 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EZElric Zweck
Elric Zweck
KTKatherine L. Thayer
Katherine L. Thayer
OHOle K. L. Helgestad
Ole K. L. Helgestad
MKManreet Kanwar
Manreet Kanwar
MAMohyee Ayouty
Mohyee Ayouty
NKNavin K. Kapur
Navin K. Kapur
Background: Cardiogenic shock (CS) is a heterogeneous syndrome with varied presentations and outcomes. We used a machine learning approach to test the hypothesis that patients with CS have distinct phenotypes at presentation, which are associated with unique clinical profiles and in‐hospital mortality. Methods and Results: We analyzed data from 1959 patients with CS from 2 international cohorts: CSWG (Cardiogenic Shock Working Group Registry) (myocardial infarction [CSWG‐MI; n=410] and acute‐on‐chronic heart failure [CSWG‐HF; n=480]) and the DRR (Danish Retroshock MI Registry) (n=1069). Clusters of patients with CS were identified in CSWG‐MI using the consensus k means algorithm and subsequently validated in CSWG‐HF and DRR. Patients in each phenotype were further categorized by their Society of Cardiovascular Angiography and Interventions staging. The machine learning algorithms revealed 3 distinct clusters in CS: "non‐congested (I)", "cardiorenal (II)," and "cardiometabolic (III)" shock. Among the 3 cohorts (CSWG‐MI versus DDR versus CSWG‐HF), in‐hospital mortality was 21% versus 28% versus 10%, 45% versus 40% versus 32%, and 55% versus 56% versus 52% for clusters I, II, and III, respectively. The "cardiometabolic shock" cluster had the highest risk of developing stage D or E shock as well as in‐hospital mortality among the phenotypes, regardless of cause. Despite baseline differences, each cluster showed reproducible demographic, metabolic, and hemodynamic profiles across the 3 cohorts. Conclusions: Using machine learning, we identified and validated 3 distinct CS phenotypes, with specific and reproducible associations with mortality. These phenotypes may allow for targeted patient enrollment in clinical trials and foster development of tailored treatment strategies in subsets of patients with CS.

21 June 2023 in JACC: Heart Failure
Verified
Journal Article
Closed access
EZElric Zweck
Elric Zweck
MKManreet Kanwar
Manreet Kanwar
SLSong Li
Song Li
SSShashank S. Sinha
Shashank S. Sinha
AGA. Reshad Garan
A. Reshad Garan
NKNavin K. Kapur
Navin K. Kapur

6 November 2023 in JACC: Heart Failure
Verified
Journal Article
Closed access
VTVan-Khue Ton
Van-Khue Ton
MKManreet K. Kanwar
Manreet K. Kanwar
BLBorui Li
Borui Li
VBVanessa Blumer
Vanessa Blumer
SLSong Li
Song Li
NKNavin K. Kapur
Navin K. Kapur

Verified
Journal Article
Open access
PDF file
CBCecilia Berardi
Cecilia Berardi
CBClaudio Bravo
Claudio Bravo
SLSong Li
Song Li
MKMaziar Khorsandi
Maziar Khorsandi
JKJeffrey E. Keenan
Jeffrey E. Keenan
CMClaudius Mahr
Claudius Mahr
The utilization of left ventricular assist devices (LVADs) in end-stage heart failure has doubled in the past ten years and is bound to continue to increase. Since the first of these devices was approved in 1994, the technology has changed tremendously, and so has the medical and surgical management of these patients. In this review, we discuss the history of LVADs, evaluating survival and complications over time. We also aim to discuss practical aspects of the medical and surgical management of LVAD patients and future directions for outcome improvement in this population.

22 August 2019 in ASAIO Journal
Verified
Journal Article
Closed access
VCVenkat Keshav Chivukula
Venkat Keshav Chivukula
JBJennifer A. Beckman
Jennifer A. Beckman
SLSong Li
Song Li
SMS. Carolina Masri
S. Carolina Masri
WLWayne C. Levy
Wayne C. Levy
AAAlberto Aliseda
Alberto Aliseda
Left ventricular assist device (LVAD) use has continued to grow. Despite recent advances in technology, LVAD patients continue to suffer from devastating complications, including stroke and device thrombosis. Among several variables affecting thrombogenicity, we hypothesize that insertion depth of the inflow cannula into the left ventricle (LV) influences hemodynamics and thrombosis risk. Blood flow patterns were studied in a patient-derived computational model of the LV, mitral valve (MV), and LVAD inflow cannula using unsteady computational fluid dynamics (CFD). Hundreds of thousands of platelets were tracked individually, for two inflow cannula insertion depth configurations (12 mm—reduced and 27 mm—conventional) using platelet-level (Lagrangian) metrics to quantify thrombogenicity. Particularly in patients with small LV dimensions, the deeper inflow cannula insertion resulted in much higher platelet shear stress histories (SH), consistent with markedly abnormal intraventricular hemodynamics. A larger proportion of platelets in this deeper insertion configuration was found to linger in the domain for long residence times (RT) and also accumulated much higher SH. The reduced inflow depth configuration promoted LV washout and reduced platelet SH. The increase of both SH and RT in the LV demonstrates the impact of inflow cannula depth on platelet activation and increased stroke risk in these patients. Inflow cannula depth of insertion should be considered as an opportunity to optimize surgical planning of LVAD therapy.